Effect of Obicetrapib on Glycaemia and New-Onset Diabetes: Pooled Analysis of BROADWAY/BROOKLYN and an Updated Meta-analysis of Cholesteryl Ester Transfer Protein (CETP) Inhibitor Trials
Pooled result · HbA1cResult — go to the resultLSMD −0.02% 95% CI −0.04 to 0.00Authors' conclusion
Obicetrapib did not adversely affect glycaemia and was associated with a numerically lower risk of NoD, consistent with a CETP inhibitor class signal of a modestly lower risk. The PREVAIL trial will provide larger-longer evidence about obicetrapib and NoD.
Study context
- Population
- Participants without diabetes at baseline in the BROADWAY and BROOKLYN trialspooled BROADWAY and BROOKLYN participants without diabetes at baseline, meta-analysis of six eligible trials reporting new-onset diabetes (NoD) · normoglycaemic 899 · prediabetes 801
- Participants
- 1,700 participants
- Comparison
- Obicetrapib 10 mg or placebo; CETP inhibition in meta-analysis
- Outcome
- HbA1c
- Follow-up
- Week 52
Methodological detailsrandomised 2:1, PRISMA-compliant, PROSPERO-registered, Mantel-Haenszel fixed-effect models, prespecified subgroup analyses, trial-level meta-regression
- Randomised 2:1
- PRISMA-compliant
- PROSPERO-registered
- Mantel-Haenszel fixed-effect models
- Prespecified subgroup analyses
- Trial-level meta-regression
Pooled result
As reported in the abstract
LSMD
−0.02%
95% CI −0.04 to 0.00
Obicetrapib vs placebo
LSMD −0.02% (95% CI −0.04 to 0.00)
Further pooled results
| Outcome | Obicetrapib | Placebo | Adjusted OR (95% CI) | |
|---|---|---|---|---|
| NoDDirectionally consistent across glycaemic strata | 6.4% | 8.5% | 0.69 (0.47–1.03) | |
| 0.512Adjusted odds ratio (log scale) |
NoD, meta-analysis of CETP inhibition
| Comparison | RR (95% CI) | |
|---|---|---|
| CETP inhibition16% lower risk; I2 = 0% | 0.84 (0.79–0.90) | |
| 0.512Relative risk (log scale) |
Restricted cubic spline analyses of NoD risk
- Associations between HDL-C, apoA1 and Lp(a) changes and NoD risk, but not HbA1c change
Original publication
Effect of Obicetrapib on Glycaemia and New-Onset Diabetes: Pooled Analysis of BROADWAY/BROOKLYN and an Updated Meta-analysis of CETP Inhibitor Trials. Eur J Prev Cardiol. Published 24 October 2026. doi:10.
Summarised from the published abstract; every number is checked against it